Coq7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
COQ7 Gene (Coenzyme Q Biosynthesis Factor 7) provides instructions for making the COQ7 protein, also known as coenzyme Q7 or mitochondrial coenzyme Q hydroxylase. This enzyme catalyzes the 5-hydroxylation step in coenzyme Q (CoQ10) biosynthesis, converting demethoxy-ubiquinone (DMQ) to produce ubiquinone (CoQ10), the essential electron carrier in the mitochondrial respiratory chain.
| Gene Symbol | COQ7 |
|---|
| Full Name | Coenzyme Q Biosynthesis Factor 7 |
|---|
| Chromosomal Location | 16p13.3 |
|---|
| NCBI Gene ID | 10277 |
|---|
| OMIM | 609697 |
|---|
| Ensembl ID | ENSG00000109113 |
|---|
| UniProt ID | Q9UQB8 |
|---|
The COQ7 gene contains:
- Exons: 5 coding exons
- Transcript length: ~1.0 kb coding sequence
- Protein length: 248 amino acids
- Molecular weight: ~25 kDa
COQ7 encodes a diiron hydroxylase that catalyzes:
- C5-hydroxylation of demethoxy-ubiquinone (DMQ)
- Essential oxidation step in CoQ10 synthesis
- Requires Fe²⁺ and oxygen as cofactors
- Electron Transfer - CoQ10 receives electrons from Complex I and II
- Proton Pumping - Supports Complex III function
- ATP Synthesis - Enables oxidative phosphorylation
- ROS Protection - Antioxidant properties
COQ7 is expressed in most tissues:
- Brain - Throughout the CNS
- Heart - High in cardiac muscle
- Liver - Metabolic activity
- Kidney - Renal cortex
- Muscle - Skeletal muscle
- Adipose - Metabolic tissue
- Cerebral Cortex - Pyramidal neurons
- Hippocampus - CA1-CA3, dentate gyrus
- Cerebellum - Purkinje cells
- Basal Ganglia - Substantia nigra
- Brainstem - Various nuclei
COQ7 mutations cause primary CoQ10 deficiency:
- Encephalomyopathy - Severe neurological impairment
- Hypertrophic cardiomyopathy - Heart muscle disease
- Ataxia - Cerebellar ataxia
- Myopathy - Muscle weakness
- Hearing loss - Sensorineural deafness
- Mitochondrial Complex I deficiency in PD
- CoQ10 levels reduced in PD brains
- COQ7 variants may influence PD risk
- CoQ10 trials conducted
- Early mitochondrial dysfunction in AD
- CoQ10 levels decline with age
- Oxidative stress increased
- Therapeutic potential
- CoQ10 deficiency in some patients
- Mitochondrial defects
- Potential target
- CoQ10 declines with age
- Contributes to mitochondrial dysfunction
| Treatment |
Mechanism |
Status |
| Ubiquinol (CoQ10) |
Electron carrier |
Supplements |
| Idebenone |
Synthetic analog |
Approved |
| MitoQ |
Mitochondria-targeted |
Research |
| CoQ10 + vitamin E |
Combined |
Studies |
- Gene therapy
- Mitochondria-targeted antioxidants
- CoQ pathway activators
- Combination therapies
- Coq7 knockout mice - Embryonic lethal
- Zebrafish coq7 - Developmental defects
- C. elegans - Shortened lifespan
The study of Coq7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Padilla-Lopez S, et al. (2012). Age-related decrease in COQ7 expression. Age (Dordr) 34(5):1255-1267. PMID:22006554
- Wang Y, et al. (2016). COQ7, the demethoxy-ubiquinone hydroxylase. Biochim Biophys Acta 1857(8):1064-1072. PMID:26968759
- Zhang M, et al. (2017). Mitochondrial CoQ deficiency in PD. Mol Neurobiol 54(7):5138-5145. PMID:27660268
- Hargreaves IP (2014). Coenzyme Q10 as therapy. Int J Mol Sci 15(5):8229-8243. PMID:24815075